Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,047Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M-9.5EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)23.4Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book5.010-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M8,900,002ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with FBT

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

FBT is held by these investors:



FBT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rapps, MichaelDirector, Director or Senior Officer of 10% Securi 2017-01-16Buy1,200$9.481140.61view
Gridley, Anthony RonaldSenior Officer 2017-01-16Sell1,800$16.94594.27view
Dinwoodie, Tyler Wayne PaulSenior Officer 2017-01-16Buy4,000$0.1769082.35view
Brown, Mark ThomasDirector 2017-01-16Sell29,300$1.368547.79view
Bebek, IvanDirector 2017-01-16Buy8,990$3.383379.59view
smith, laurie james10% Security Holder, Director, Senior Officer 2017-01-16Buy7,500$0.4128585.37view
MEHR, JEFFREYSenior Officer 2017-01-13Sell50,000$27.91321.39view
Squibb, Geoffrey WayneDirector 2017-01-13Buy267$6.271775.76view
Smith, DavidSenior Officer 2017-01-13Sell15,000$60.3894.78view
Rowlands, William BruceDirector, Senior Officer 2017-01-13Buy20,000$0.1578306.67view

Quarterly/Annual Reports about FBT:

    News about FBT:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    Top Biotech ETFs to Buy Jun 22 2017
    Why Biotech Stocks Are Hitting the Skids May 15 2017
    Ionis Pharmaceuticals’ Valuation Compared to Its Peers Mar 21 2017
    Time to Buy Biotech ETF? Mar 13 2017
    Alnylam Pharmaceuticals’s Therapies to Treat hATTR Amyloidosis Feb 28 2017
    Biotech ETFs Powered by Q4 Earnings Feb 10 2017
    Politics Plague Biotech ETFs Feb 01 2017
    What Lies Ahead for Biotech ETFs in Trump Era? Jan 27 2017
    Here's How to Play the Biotech Rebound Jan 25 2017
    Fidelity Biotech Fund: Better than the Index? Jan 16 2017
    Here's Why Merrimack Pharmaceuticals Inc. Fell 47.3% in 2016 Jan 10 2017
    United Therapeutics: Will RemoSynch Become a Key Growth Driver? Dec 29 2016
    How Could Gilead Sciences Restore Its Growth? Dec 01 2016
    Why Neurocrine Biosciences May See Higher Losses in 2016 Dec 01 2016
    5 Reasons to Buy 5 Low P/E Biotech ETFs Nov 14 2016
    Why Arrowhead Pharmaceuticals Inc. Is Plummeting Today Nov 09 2016
    What Drove Regeneron’s 3Q16 Performance? Nov 09 2016
    Why Did Halozyme Therapeutics, Inc. Plunge 29.5% in October? Nov 08 2016
    Biotech ETFs Slumping on Q3 Results Nov 08 2016
    Once Beloved Momentum ETF Loses Its Momo Oct 27 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat

    {{numOfNotice}}